指南与共识头颈与中枢神经肿瘤支持与姑息治疗

实体瘤脑转移系统治疗临床试验设计:RANO-BM工作组指南

Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.
指南 / 共识 · Lancet Oncol · 2018-01-01

RANO-BM工作组针对实体瘤脑转移患者系统治疗临床试验设计发布指南,提出应根据药物CNS活性可能性分三种情形决定此类患者的纳入或排除,并讨论 retrospective 研究的局限及CNS终点选择。

要点

  • 药物CNS活性可能性分三种情形决定脑转移患者纳入或排除。
  • 应在药物开发早期纳入脑转移患者以获取CNS疗效信号。
  • 需关注脑转移患者特有的试验设计问题及CNS终点选择。

核心结论

  • 应在药物或方案临床开发早期纳入脑转移患者,以产生适当的CNS疗效或非疗效信号。

研究设计与样本

  • 本指南由RANO-BM工作组制定,基于工作组共识提出推荐。

主要发现

  • 活动性CNS疾病患者常被排除在临床试验之外,CNS疗效数据通常获取较晚或缺失。
  • 回顾性研究在确定系统药物CNS疗效方面存在局限性。
  • 根据药物CNS活性可能性分三种情形讨论脑转移患者的纳入或排除。

关键数值与推荐

  • 情形一:药物被认为极不可能具有CNS抗肿瘤活性或疗效。
  • 情形二:药物被认为极有可能具有CNS活性或疗效。
  • 情形三:药物CNS活性或疗效的基线信息极少。

临床怎么用

  • 根据药物CNS活性可能性,在系统治疗试验中优化纳入或排除脑转移患者。
  • 在试验设计中选用适合脑转移患者的CNS终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with active CNS disease are often excluded from clinical trials, and data regarding the CNS efficacy of systemic agents are usually obtained late in the drug development process or not at all. In this guideline from the Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) working group, we provide detailed recommendations on when patients with brain metastases from solid tumours should be included or excluded in clinical trials of systemic agents. We also discuss the limitations of retrospective studies in determining the CNS efficacy of systemic drugs. Inclusion of patients with brain metastases early on in the clinical development of a drug or a regimen is needed to generate appropriate CNS efficacy or non-efficacy signals. We consider how to optimally incorporate or exclude such patients in systemic therapy trials depending on the likelihood of CNS activity of the agent by considering three scenarios: drugs that are considered very unlikely to have CNS antitumour activity or efficacy; drugs that are considered very likely to have CNS activity or efficacy; and drugs with minimal baseline information on CNS activity or efficacy. We also address trial design issues unique to patients with brain metastases, including the selection of appropriate CNS endpoints in systemic therapy trials.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Camidge DR, Lee EQ, Lin NU, et al. Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncol. 2018. PMID: 29304358. doi:10.1016/S1470-2045(17)30693-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。